• Dr. Rietiker brings extensive experience to the role, having held leadership positions at global pharmaceutical and medical device companies and overseen several major corporate acquisitions.

Zurich, April 23, 2025 – MetrioPharm AG, a pharmaceutical company focused on developing treatments for inflammatory and infectious diseases, announced today that Dr. Stephan Rietiker was unanimously elected as the new Chairman of the Board of Directors at its first meeting.

Dr. Rietiker stated, “I am grateful to the Board members for their vote and confidence in me. Our shared objective will be to successfully develop MP1032 clinically and quickly bring it to market. The company is well-positioned to achieve this. We appreciate the dedication of the outgoing board members over the past several years, which has led to impressive results, including in the COVID-19 indication. Our task will be to build upon this effectively, and I am optimistic about the work ahead.”

MetrioPharm CEO Thomas Christély commented, “With Dr. Rietiker, MetrioPharm AG gains a highly qualified pharmaceutical expert with a proven track record in both management and investment. His deep understanding of the European and US markets will be invaluable in helping the company navigate upcoming challenges on its path to commercialization. On behalf of the management and the entire MetrioPharm AG team, I extend a warm welcome to him and all the newly elected Board members.”

Dr. Stephan Rietiker, a trained physician licensed to practice in both Switzerland and the United States, began his career in Switzerland. He has since become a respected expert and leader in healthcare and technology. His executive roles at global pharmaceutical and medical technology companies like Roche, Boehringer Mannheim, Schering Plough, Covance, Centerpulse, and LifeWatch have established his reputation as a well-rounded and successful manager and turnaround specialist with significant experience in the U.S. market. Following a turnaround of LifeWatch and its subsequent sale to BioTelemetry Inc., Dr. Rietiker joined the Board of BioTelemetry, where he actively supported Philips’ acquisition of BioTelemetry Inc for USD 2.8 billion in 2021. In 2022, he founded EpiLunar Partners AG in Zug, Switzerland, to invest in and develop innovative and marketable solutions in the digital health sector.

###

About MetrioPharm AG

MetrioPharm AG is a privately held, clinical-stage biotech company specializing in therapies for inflammatory and infectious diseases.

MetrioPharm’s focus is on modulating immune metabolism using first-in-class, self-regulating drug candidates. The Company’s platform has created small-molecule metabolic modulators that have shown pre-clinical and clinical effectiveness in a broad spectrum of inflammatory and infectious diseases, with a strong safety record.

Using this core technology, MetrioPharm has developed a pipeline of disease-specific drug combinations aimed at inflammatory, autoimmune, and degenerative diseases. Preclinical and clinical efficacy data have been obtained in studies of multiple sclerosis, arthritis, sepsis, inflammatory bowel disease, and psoriasis. The Company is currently investigating several orphan indications, with Duchenne muscular dystrophy as its primary focus.

In a secondary line of development, MetrioPharm is applying its technology to target infectious diseases like COVID-19 – also as a proof of concept to improve pandemic preparedness. With support from a grant from the European Health Emergency Preparedness and Response Authority (HERA), a Phase IIa exploratory study assessed the effect on hospitalized COVID-19 patients. The study confirmed the favorable clinical safety profile of MP1032 and presented compelling efficacy data.

The Company’s headquarters are in Zurich, with a subsidiary for R&D activities located in Berlin.

Forward-looking statements

This press release includes forward-looking statements that are subject to risks and uncertainties and reflect MetrioPharm AG’s assessment as of the date of this release. These forward-looking statements are not guarantees but are subject to various risks and uncertainties. No liability, warranty, or claim is made regarding the timeliness, accuracy, or completeness of this data and information, and no reliance should be placed on it, either explicitly or implicitly.

Contacts

MetrioPharm
Corporate Communications & Press Relations
presse@metriopharm.com
Phone +41 44 552 7198

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners      
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68

“`